The Emerging Gait Dysfunction Phenotype in Idiopathic Parkinson’s Disease
暂无分享,去创建一个
E. Disbrow | D. Standaert | G. Cutter | T. Anthony | F. Skidmore | C. Hurt | A. Nicholas | A. Gerstenecker | A. Bashir | W. Monroe | L. Jololian | T. Denny
[1] R. Barker,et al. The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.
[2] W. Au,et al. Non‐motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life , 2018, European journal of neurology.
[3] A. Singleton,et al. Predicting progression in patients with Parkinson's disease , 2017, The Lancet Neurology.
[4] Jeffrey M. Hausdorff,et al. Do cognition and other non-motor symptoms decline similarly among patients with Parkinson’s disease motor subtypes? Findings from a 5-year prospective study , 2017, Journal of Neurology.
[5] A. Tessitore,et al. Cognitive impairment is associated with Hoehn and Yahr stages in early, de novo Parkinson disease patients. , 2017, Parkinsonism & related disorders.
[6] C. Tanner,et al. Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.
[7] C. Tanner,et al. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? , 2016, Parkinsonism & related disorders.
[8] C. Ritchie,et al. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease , 2016, BMC Neurology.
[9] H. Shang,et al. Non‐motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson′s disease patients , 2016, Acta neurologica Scandinavica.
[10] Giuseppe Orefice,et al. The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients , 2013, PloS one.
[11] J. Jankovic,et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale , 2013, Movement disorders : official journal of the Movement Disorder Society.
[12] J. Massano,et al. Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management , 2012, Front. Neur..
[13] A. Singleton,et al. The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.
[14] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[15] Bart Post,et al. UvA-DARE ( Digital Academic Repository ) Clinimetrics , clinical profile and prognosis in early Parkinson ’ s disease , 2009 .
[16] Nobutaka Hattori,et al. Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations , 2006, Movement disorders : official journal of the Movement Disorder Society.
[17] D. Aarsland,et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[18] I. McKeith,et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[19] W. Poewe,et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[20] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[21] C. Clarke. A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? , 2004, Movement disorders : official journal of the Movement Disorder Society.
[22] H. Braak,et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.
[23] Hansjürgen Bratzke,et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.
[24] Andrew J. Lees,et al. Treatment of Parkinson's disease: levodopa as the first choice , 2002, Journal of Neurology.
[25] J. Jankovic,et al. Variable expression of Parkinson's disease , 1990, Neurology.
[26] P. Riederer,et al. Distinction between benign and malignant type of parkinson's disease , 1979, Clinical Neurology and Neurosurgery.
[27] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[28] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[29] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[30] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .